TrialCancer medicine2019

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.

Alexander Egle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.